Ascendis Pharma A/S (NASDAQ:ASND) Stake Boosted by RA Capital Management L.P.

RA Capital Management L.P. boosted its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 4.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,112,744 shares of the biotechnology company's stock after purchasing an additional 402,316 shares during the quarter. Ascendis Pharma A/S makes up approximately 18.3% of RA Capital Management L.P.'s holdings, making the stock its biggest position. RA Capital Management L.P. owned 16.66% of Ascendis Pharma A/S worth $1,392,221,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. The Manufacturers Life Insurance Company grew its position in shares of Ascendis Pharma A/S by 16.3% during the fourth quarter. The Manufacturers Life Insurance Company now owns 82,955 shares of the biotechnology company's stock valued at $11,420,000 after purchasing an additional 11,648 shares in the last quarter. Quarry LP purchased a new position in Ascendis Pharma A/S during the 4th quarter valued at approximately $96,000. Aquatic Capital Management LLC bought a new stake in Ascendis Pharma A/S in the 4th quarter worth approximately $230,000. Virtus ETF Advisers LLC raised its holdings in shares of Ascendis Pharma A/S by 3.9% during the 4th quarter. Virtus ETF Advisers LLC now owns 2,676 shares of the biotechnology company's stock worth $368,000 after acquiring an additional 100 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. raised its holdings in shares of Ascendis Pharma A/S by 54.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company's stock worth $375,226,000 after acquiring an additional 960,504 shares in the last quarter.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND traded up $4.59 on Friday, hitting $172.06. 1,175,394 shares of the company's stock were exchanged, compared to its average volume of 494,883. The stock has a market capitalization of $10.49 billion, a price-to-earnings ratio of -24.23 and a beta of 0.41. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $183.00. The business's 50 day simple moving average is $155.31 and its two-hundred day simple moving average is $140.33.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The company had revenue of $123.97 million for the quarter, compared to the consensus estimate of $98.56 million. Equities analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on ASND shares. Wedbush boosted their price target on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an "outperform" rating in a research report on Friday. JPMorgan Chase & Co. boosted their target price on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an "overweight" rating in a report on Friday. The Goldman Sachs Group increased their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a report on Thursday, February 13th. Morgan Stanley set a $180.00 price objective on Ascendis Pharma A/S in a research note on Tuesday, February 18th. Finally, UBS Group initiated coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a "buy" rating and a $196.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $211.40.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.